Travere Therapeutics Inc. (tvtx 2.25 03/01/29)
13F holders, Q2 2025 (June 30)3holders +2
2new positions
0sold out
$0.95avg. 13F price*
At the end of Q2 2025, 3 institutions reported holding Travere Therapeutics Inc. (tvtx 2.25 03/01/29) in their 13F filings, up 2 from Q1 2025. 2 opened new positions and 0 sold out. The largest holders were Graham Capital Management, L.P. ($39.7M), Janus Henderson Group PLC ($10.8M) and New York State Common Retirement Fund ($2.6M).
- Company
- Travere Therapeutics Inc. (tvtx 2.25 03/01/29)
- CUSIP
- 89422GAA5
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $42.3M |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 45,370,000 shares bought, net +45,370,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Graham Capital Management, L.P. | 1.21% | New | 41,667,000 | $39.7M |
| Janus Henderson Group PLC | 0.01% | Add +9.6% | 11,391,000 | $10.8M |
| New York State Common Retirement Fund | 0.00% | New | 2,706,000 | $2.6M |
"% of holder's portfolio" is TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29)'s weight in each manager's 13F, not the share of Travere Therapeutics Inc. (tvtx 2.25 03/01/29) the manager owns.